NEW BRUNSWICK, N.J. - Johnson & Johnson agreed on Nov. 16 to acquire clinical-stage biotech Ollin Biosciences for $2.2 billion upfront and up to $1.125 billion in milestones to gain a Phase 3 eye-disease antibody.
Blackstone Commits $750 Million for Phase 3 Trials
Contingent on the deal closing before the end of 2026, Johnson & Johnson will enter a separate funding pact with Blackstone Life Sciences. Blackstone will pay $750 million over multiple years to fully fund Phase 3 testing of OLN324 in exchange for regulatory milestones and single-digit sales royalties. Launched in 2025 with backing from Arch Venture Partners and TCGX, Austin-based Ollin originally licensed OLN324 from Shanghai-based Innovent Biologics.
Dual-Target Antibody Aims to Extend Dosing Intervals
OLN324 is a small-format bispecific antibody blocking VEGF and Ang2 proteins in wet age-related macular degeneration and diabetic macular edema, two leading causes of vision loss affecting over 40 million people globally. Four Phase 3 studies are comparing OLN324 against Regeneron's Eylea or Lucentis. "OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control," J&J Ophthalmology Vice President Kip Connor said in the company's release, noting potential for longer intervals between eye injections.
Analysts Weigh High Price in Crowded Market
The deal expands J&J's prescription eye-medicine pipeline beyond its contact lens and surgical units to challenge Roche's Vabysmo, which is nearing $5 billion in annual sales. Although Phase 1b data favored OLN324, RBC Capital Markets analyst Trung Huynh cautioned in a note cited by BioPharma Dive that the price appears high and differentiation in a crowded market remains uncertain.


